Myriad Genetics stock
MYGNNASDAQMyriad Genetics, Inc., HealthcareISIN US62855J1043
40Score 40 out of 100, Weak
Price and trend
82 / 100
Price history
−13% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 28% below its 52-week high. Largest decline in 20 years: 94% (September 2018 to July 2026).
Chart figures for advanced users
- SMA 50$4.70
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.86
- The lowest closing price of the last twelve months.
- Resistance$7.91
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Myriad Genetics, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $544.84M, is number 36 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $824.5M (down 1.6% year on year) and a loss of $365.9M.
- For fiscal 2026, analysts expect on average revenue of $780.73M (down 5.3%) and adjusted earnings per share of −$0.70.
Show more
- MEQIRI Score 40 out of 100 (Weak): rank 539 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 26% since 2019.Capital allocation 18
- Loss-makingLoss of $129.1M over the last 12 months.Fundamentals 23
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 43
Its standout strength is technical analysis, while fundamentals and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 2.6% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating −8%, net −44%. Last 12 months: net −16%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 101 days
- Last reported
- 4 Nov 2026EPS reported −$0.11 (expected −$0.20)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.70+2.3%
- Revenue
- $780.73M+0.4%
- Earnings per share
- −$0.62−5.5%
- Revenue
- $788.23M−3.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −16.8%2026 guidance reaffirmed: revenue of $860 million to $880 million, adjusted EBITDA of $37 million to $49 million.
“We are reaffirming our full year 2026 financial guidance, including revenue of $860 million to $880 million, adjusted gross margin of 68% to 69% and adjusted EBITDA of $37 million to $49 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $27,638 in total. One insider sold, $66,843 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Myriad Genetics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- NeoGenomicsNEO $2.15B39
- VeracyteVCYT $1.99B53
- PersonalisPSNL $1.72B41
- GeneDx HoldingsWGS $1.55B37
- OPKO HealthOPK $1.24B37
- Castle BiosciencesCSTL $1.06B45
- Fulgent GeneticsFLGT $694.28M36
- VoxelVOX.WA $400.11M82
ETFs that hold Myriad Genetics
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.38% | 0.50% | €127.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.06% | 0.40% | €1.5B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
Show 2 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.